Patents by Inventor H. Uri Saragovi

H. Uri Saragovi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of use of Trk receptor modulators
    Patent number: 8648169
    Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 11, 2014
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventor: H. Uri Saragovi
  • Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein
    Patent number: 8563520
    Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 22, 2013
    Assignee: McGill University
    Inventor: H. Uri Saragovi
  • METHODS OF USE OF TRK RECEPTOR MODULATORS
    Publication number: 20100048461
    Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
    Type: Application
    Filed: December 5, 2007
    Publication date: February 25, 2010
    Inventor: H. Uri Saragovi
  • Intraocular pressure-regulated early genes and uses thereof
    Publication number: 20080305103
    Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
    Type: Application
    Filed: May 22, 2008
    Publication date: December 11, 2008
    Inventor: H. Uri Saragovi
  • GD2 ligands
    Patent number: 7423114
    Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: September 9, 2008
    Assignee: McGill University
    Inventors: Martin Gagnon, H. Uri Saragovi
  • Design of hormone-like antibodies with agonistic and antagonistic functions
    Patent number: 6610500
    Abstract: The present invention relates to an agonistic anti-human TrkA mAb 5C3 which recognizes the NGF docking site. Such antibodies may be used for the treatment, diagnosis or prevention of neurological diseases, neuromas and neoplastic tumors which express TrkA receptors. Also these antibodies may be used to develop and screen for pharmaceutical agents which are agonistic or antagonistic to NGF binding to the TrkA receptors.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: August 26, 2003
    Assignee: McGill University
    Inventors: H. Uri Saragovi, Lynne LeSauteur